|
2025
|
Invention
|
Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxyben... |
|
2024
|
Invention
|
Compounds useful as kinase inhibitors.
This invention relates to novel compounds. The compounds ... |
|
2023
|
Invention
|
Compounds useful as kinase inhibitors. This invention relates to novel compounds. The compounds o... |
|
|
Invention
|
Bcl2 formulations. Disclosed are pharmaceutical formulations containing the compound of Formula (... |
|
2022
|
Invention
|
Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor. Provid... |
|
|
Invention
|
Crystalline forms of ret inhibitor and preparation thereof.
Provided herein are methods of prepa... |
|
|
Invention
|
Cocrystalline forms of a bruton's tyrosine kinase inhibitor.
Provided herein are cocrystalline f... |
|
|
Invention
|
Cocrystalline forms of a bruton's tyrosine kinase inhibitor. Provided herein are cocrystalline fo... |
|
|
Invention
|
Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabi... |
|
2021
|
Invention
|
Combination of a ret inhibitor and a platinum agent for use in the treatment of cancer. The discl... |
|
|
Invention
|
Ret inhibitor combination therapy for treating cancer. The disclosure provides a method for treat... |
|
|
Invention
|
Compositions and methods for preventing brain metastases. The disclosure provides compositions an... |
|
|
Invention
|
Methods of diagnosing and treating cancer.
A variety of different point mutations in NTRK1, NTRK... |
|
|
Invention
|
Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido... |
|
|
Invention
|
Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers.... |
|
|
Invention
|
Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)meth... |
|
|
Invention
|
Crystalline ret inhibitor.
Provided herein is a crystalline form of selpercatinib useful in the ... |
|
|
Invention
|
Crystalline ret inhibitor. Provided herein is a crystalline form of selpercatinib useful in the t... |
|
|
Invention
|
Point mutations in trk inhibitor-resistant cancer and methods relating to the same.
Provided her... |
|
2020
|
Invention
|
Dosing of a bruton's tyrosine kinase inhibitor.
The present invention provides a method of admin... |
|
|
Invention
|
Dosing of a bruton's tyrosine kinase inhibitor. The present invention provides a method of admini... |
|
|
Invention
|
Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyc... |
|
|
Invention
|
Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyri... |
|
|
Invention
|
Methods of treating pediatric cancers. A method of treating a pediatric cancer in a subject in ne... |
|
2019
|
Invention
|
Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methy... |
|
|
Invention
|
Treatment of trk-associated cancers.
Provided herein are compounds and pharmaceutical compositio... |
|
|
Invention
|
Treatment of trk-associated cancers. Provided herein are compounds and pharmaceutical composition... |
|
2018
|
Invention
|
Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrim... |
|
|
Invention
|
Formulations of a macrocyclic trk kinase inhibitor.
The present application in some embodiments ... |
|
|
Invention
|
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabic... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer, autoimmune disease and immunologic-based... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer,
autoimmune disease and immunologic-base... |
|
2017
|
Invention
|
Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof. In some embodiments,... |
|
|
P/S
|
Pharmaceuticals; therapeutic pharmaceutical for the treatment of cancer, autoimmune disease and i... |
|
2016
|
P/S
|
Pharmaceuticals; full line of pharmaceutical preparations; pharmaceutical preparations for the tr... |
|
|
P/S
|
full line of pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer... |
|
|
P/S
|
pharmaceutical preparations for the treatment of cancer, autoimmune disease and immunologic-based... |
